A listing of human tumor antigens recognized by T cells: March 2004 update
暂无分享,去创建一个
[1] P. Romero,et al. A peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3 , 2005, Immunogenetics.
[2] Pierre van der Bruggen,et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family , 2005, Immunogenetics.
[3] H. Rammensee,et al. Induction of Adipophilin-Specific Cytotoxic T Lymphocytes Using a Novel HLA-A2-Binding Peptide That Mediates Tumor Cell Lysis , 2004, Cancer Research.
[4] Jonathan W. Yewdell,et al. Immune recognition of a human renal cancer antigen through post-translational protein splicing , 2004, Nature.
[5] J. Gebert,et al. Identification of an HLA-A0201-Restricted CTL Epitope Generated by a Tumor-Specific Frameshift Mutation in a Coding Microsatellite of the OGT Gene , 2003, Journal of Clinical Immunology.
[6] G. Camerino,et al. A family of rapidly evolving genes from the sex reversal critical region in Xp21 , 1995, Mammalian Genome.
[7] E. Shevach,et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. , 2004, Immunity.
[8] F. Brasseur,et al. Sequence and expression pattern of the human MAGE2 gene , 2004, Immunogenetics.
[9] Francine Jotereau,et al. Identification of Five New HLA-B*3501-Restricted Epitopes Derived from Common Melanoma-Associated Antigens, Spontaneously Recognized by Tumor-Infiltrating Lymphocytes 1 , 2003, The Journal of Immunology.
[10] R. Longhi,et al. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. , 2003, Cancer research.
[11] F. Lemonnier,et al. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. , 2003, Cancer research.
[12] T. Nukiwa,et al. Identification of a CTL‐directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA‐B52+ and HLA‐62+ cancer patients , 2003, European journal of immunology.
[13] P. Dalerba,et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. , 2003, Cancer research.
[14] L. Kanz,et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. , 2003, Blood.
[15] K. Black,et al. Molecular and Functional Analysis of Tyrosinase-Related Protein (TRP)-2 as a Cytotoxic T Lymphocyte Target in Patients With Malignant Glioma , 2003, Journal of immunotherapy.
[16] P. Robbins,et al. Identification of a Mutated Receptor-Like Protein Tyrosine Phosphatase κ as a Novel, Class II HLA-Restricted Melanoma Antigen1 , 2003, The Journal of Immunology.
[17] Dong-lin Wang,et al. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] Ken Jung,et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[19] Vladimir Brusic,et al. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] K. Azuma,et al. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. , 2003, Cancer research.
[21] M. Griffioen,et al. CD4+ Th2 Cell Recognition of HLA-DR-Restricted Epitopes Derived from CAMEL: A Tumor Antigen Translated in an Alternative Open Reading Frame , 2003, The Journal of Immunology.
[22] A. Sette,et al. Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1 , 2003, The Journal of Immunology.
[23] Angela Bachi,et al. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. , 2003, Blood.
[24] G. Pawelec,et al. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes , 2003, Cancer Immunology, Immunotherapy.
[25] L. Frati,et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] J. Dipersio,et al. Identification of HLA‐A3‐restricted CD8+ T cell epitopes derived from mammaglobin‐A, a tumor‐associated antigen of human breast cancer , 2002, International journal of cancer.
[27] Y. Horiguchi,et al. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] Jonathan J. Lewis,et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Hans-Georg Rammensee,et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. , 2002, Cancer research.
[30] Thierry Boon,et al. Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.
[31] Y. Ward,et al. Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. , 2002, Cancer research.
[32] J. Prieto,et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] I. Pollack,et al. Identification of a Novel HLA-A*0201-restricted, Cytotoxic T Lymphocyte Epitope in a Human Glioma-associated Antigen, Interleukin 13 Receptor α2 Chain , 2002 .
[34] W. Sommergruber,et al. Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the Novel Overexpressed Tumor Antigen Calcium-Activated Chloride Channel 2 , 2002, The Journal of Immunology.
[35] Francesco M Marincola,et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.
[36] F. Marincola,et al. Identification of a Mutated Fibronectin As a Tumor Antigen Recognized by CD4+T Cells , 2002, The Journal of experimental medicine.
[37] K. Kamiguchi,et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] S. Rosenberg,et al. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. , 2002, Cancer research.
[39] S. Bézieau,et al. A ras-Mutated Peptide Targeted by CTL Infiltrating a Human Melanoma Lesion1 , 2002, The Journal of Immunology.
[40] R. Rees,et al. Prediction of an HLA-DR-binding peptide derived from Wilms’ tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124–138)-pulsed dendritic cells generated according to an optimised protocol , 2002, Cancer Immunology, Immunotherapy.
[41] P. Robbins. Immune Recognition of Cancer—Tumor Antigens , 2002 .
[42] G. Nicolini,et al. Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. , 2002, Tissue antigens.
[43] F. Lemonnier,et al. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. , 2002, Blood.
[44] S. Fujita,et al. Identification of a novel WT1‐derived peptide which induces human leucocyte antigen‐A24‐restricted anti‐leukaemia cytotoxic T lymphocytes , 2002, British journal of haematology.
[45] S. Rosenberg,et al. Identification of BING-4 Cancer Antigen Translated From an Alternative Open Reading Frame of a Gene in the Extended MHC Class II Region Using Lymphocytes From a Patient With a Durable Complete Regression Following Immunotherapy , 2002, The Journal of Immunology.
[46] Danila Valmori,et al. Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma1 , 2002, The Journal of Immunology.
[47] S. Rosenberg,et al. Pre-Existing Immunity to Tyrosinase-Related Protein (TRP)-2, a New TRP-2 Isoform, and the NY-ESO-1 Melanoma Antigen in a Patient with a Dramatic Response to Immunotherapy , 2002, The Journal of Immunology.
[48] I. Pollack,et al. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[49] B. J. Van den Eynde,et al. Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. , 2002, Cancer immunity.
[50] S. Rosenberg,et al. Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen. , 2001, Cancer research.
[51] W. Hahn,et al. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[52] V. Brusic,et al. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells , 2001, British Journal of Cancer.
[53] J. Nesland,et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[54] P. Hwu,et al. Retrovirally Transduced Human Dendritic Cells Can Generate T Cells Recognizing Multiple MHC Class I and Class II Epitopes from the Melanoma Antigen Glycoprotein 100 , 2001, The Journal of Immunology.
[55] F. Marincola,et al. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. , 2001, Cancer research.
[56] J. Becker,et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. , 2001, Cancer research.
[57] S. Rosenberg,et al. Melanoma-Reactive CD8 + T Cells Recognize a Novel Tumor Antigen Expressed in a Wide Variety of Tumor Types , 2001, Journal of immunotherapy.
[58] Yan P. Yuan,et al. Frameshift peptide‐derived T‐cell epitopes: A source of novel tumor‐specific antigens , 2001, International journal of cancer.
[59] R. Kridel,et al. An Alternative Open Reading Frame of the Human Macrophage Colony-Stimulating Factor Gene Is Independently Translated and Codes for an Antigenic Peptide of 14 Amino Acids Recognized by Tumor-Infiltrating Cd8 T Lymphocytes , 2001, The Journal of experimental medicine.
[60] P. Coulie,et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. , 2001, Cancer research.
[61] E. Schaftingen,et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. , 2001, Cancer research.
[62] D. B. Yehuda,et al. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern , 2001, FEBS letters.
[63] H. Tanaka,et al. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53 , 2001, British Journal of Cancer.
[64] S. Rosenberg,et al. Isolation of a New Melanoma Antigen, MART-2, Containing a Mutated Epitope Recognized by Autologous Tumor-Infiltrating T Lymphocytes1 , 2001, The Journal of Immunology.
[65] J. Becker,et al. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. , 2001, Cancer research.
[66] Ferry Ossendorp,et al. Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis , 2001, The Journal of experimental medicine.
[67] L. Old,et al. Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. , 2001, Cancer immunity.
[68] Masaaki Ito,et al. Identification of SART3‐derived peptides capable of inducing HLA‐A2‐restricted and tumor‐specific CTLs in cancer patients with different HLA‐A2 subtypes , 2000, International journal of cancer.
[69] H. Shiku,et al. A novel human HER2‐derived peptide homologous to the mouse Kd‐restricted tumor rejection antigen can induce HLA‐A24‐restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals , 2000, European journal of immunology.
[70] J. Murray,et al. Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides , 2000, Cancer Immunology, Immunotherapy.
[71] G. Salvesen,et al. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas , 2000, Current Biology.
[72] P. Coulie,et al. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. , 2000, Cancer research.
[73] E. Thiel,et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. , 2000, Cancer research.
[74] H. Rammensee,et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. , 2000, Cancer research.
[75] T. Boon,et al. Identification on a human sarcoma of two new genes with tumor-specific expression. , 2000, Cancer research.
[76] C. Noppen,et al. Naturally processed and concealed HLA‐A2.1‐restricted epitopes from tumor‐associated antigen tyrosinase‐related protein‐2 , 2000 .
[77] S. Rosenberg,et al. Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules , 2000, The Journal of Immunology.
[78] A. Anichini,et al. Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization. , 2000, The Journal of investigative dermatology.
[79] T. Boon,et al. MAGE‐B5, MAGE‐B6, MAGE‐C2, and MAGE‐C3: four new members of the MAGE family with tumor‐specific expression , 2000, International journal of cancer.
[80] K. Tanaka,et al. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. , 2000, Cancer research.
[81] M. Probst-Kepper,et al. Cytolytic T Lymphocytes Raised Against a Human Bladder Carcinoma Recognize an Antigen Encoded by Gene MAGE-A121 , 2000, The Journal of Immunology.
[82] R. Clark,et al. b3a2 BCR–ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia , 2000, British journal of haematology.
[83] H. Hirai,et al. Generation of HLA‐DRB1*1501‐restricted p190 minor bcr–abl (e1a2)‐specific CD4+ T lymphocytes , 2000, British journal of haematology.
[84] A. Moreau-Aubry,et al. A Processed Pseudogene Codes for a New Antigen Recognized by a Cd8+ T Cell Clone on Melanoma , 2000, The Journal of experimental medicine.
[85] J. Hipp,et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[86] F. Marincola,et al. A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12 , 2000, The Journal of Immunology.
[87] N. Altorki,et al. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. , 2000, Cancer letters.
[88] Yao-Tseng Chen,et al. CT10: A new cancer‐testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational‐difference analysis , 2000, International journal of cancer.
[89] H. Fujita,et al. Identification of a Gene Coding for a New Squamous Cell Carcinoma Antigen Recognized by the CTL1 , 2000, The Journal of Immunology.
[90] P. Dalerba,et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[91] D. Jäger,et al. Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma , 2000, The Journal of experimental medicine.
[92] H. Sugiyama,et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product , 2000, Immunogenetics.
[93] V. Brusic,et al. Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells , 2000 .
[94] M. Probst-Kepper,et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.
[95] V. Brusic,et al. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[96] M. Vikkula,et al. New Helicase Gene Antigen Generated by a Point Mutation in a Anti-Melanoma CTL Directed Against an High Frequency of Autologous , 2000 .
[97] S. Fujita,et al. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. , 2000, Blood.
[98] M. Probst-Kepper,et al. A New Antigen Recognized by Cytolytic T Lymphocytes on a Human Kidney Tumor Results from Reverse Strand Transcription , 1999, The Journal of experimental medicine.
[99] F. Foury,et al. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. , 1999, Cancer research.
[100] M. Nakao,et al. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. , 1999, Journal of immunology.
[101] C. Figdor,et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. , 1999, Cancer research.
[102] Thierry Boon,et al. DNA Methylation Is the Primary Silencing Mechanism for a Set of Germ Line- and Tumor-Specific Genes with a CpG-Rich Promoter , 1999, Molecular and Cellular Biology.
[103] G. Cornelis,et al. A MAGE‐A4 peptide presented by HLA‐A2 is recognized by cytolytic T lymphocytes , 1999, European journal of immunology.
[104] K. Hirata,et al. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes. , 1999, Journal of immunology.
[105] G. Cornelis,et al. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. , 1999, Journal of immunology.
[106] K. Shirouzu,et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. , 1999, Cancer research.
[107] F. Brasseur,et al. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. , 1999, Cancer research.
[108] H. Fujita,et al. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. , 1999, Tissue antigens.
[109] J. van Bergen,et al. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. , 1999, Blood.
[110] A. Sette,et al. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[111] P. Schrier,et al. Interleukin‐2‐induced, melanoma‐specific T cells recognize camel, an unexpected translation product of LAGE‐1 , 1999, International journal of cancer.
[112] A Sette,et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. , 1999, Journal of immunology.
[113] F. Triebel,et al. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. , 1999, Journal of immunology.
[114] A. Ribas,et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. , 1999, Cancer research.
[115] P. Chomez,et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. , 1999, Cancer research.
[116] H. Rammensee,et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. , 1999, Blood.
[117] W. Hahn,et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.
[118] F. Brasseur,et al. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. , 1999, Journal of immunology.
[119] P. Dalerba,et al. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. , 1999, Cancer research.
[120] S. Rosenberg,et al. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. , 1999, Science.
[121] S. Rosenberg,et al. Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.
[122] K. Itoh,et al. A newly identified MAGE‐3‐derived epitope recognized by HLA‐A24‐restricted cytotoxic T lymphocytes , 1999, International journal of cancer.
[123] H. Yamana,et al. Identification of a SART‐1‐derived peptide capable of inducing HLA‐A24‐restricted and tumor‐specific cytotoxic T lymphocytes , 1999, International journal of cancer.
[124] A. Eggermont,et al. Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.
[125] Matteo Bellone,et al. Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 , 1999, The Journal of experimental medicine.
[126] J. Shabanowitz,et al. Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.
[127] E. Angevin,et al. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. , 1999, Journal of immunology.
[128] T. Hercend,et al. A MAGE‐6‐encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion , 1999, European journal of immunology.
[129] T. Hercend,et al. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation , 1999, European journal of immunology.
[130] G. Parmiani,et al. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. , 1999, Journal of immunology.
[131] Y. Abe,et al. Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. , 1999, Blood.
[132] F. Tanaka,et al. A MAGE‐1‐encoded HLA‐A24‐binding synthetic peptide induces specific anti‐tumor cytotoxic T lymphocytes , 1999, International journal of cancer.
[133] A. Sette,et al. Identification of HLA-A 3-restricted Cytotoxic T Lymphocyte Epitopes from Carcinoembryonic Antigen and HER-2 / neu by Primary in Vitro Immunization with Peptide-pulsed Dendritic Cells 1 , 1999 .
[134] K. Sakaguchi,et al. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. , 1998, Journal of immunology.
[135] M. Miwa,et al. Expression of alpha-fetoprotein and prostate-specific antigen genes in several tissues and detection of mRNAs in normal circulating blood by reverse transcriptase-polymerase chain reaction. , 1998, Japanese journal of clinical oncology.
[136] J. Shabanowitz,et al. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. , 1998, Cancer research.
[137] P. Ciborowski,et al. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. , 1998, Cancer research.
[138] A. Sette,et al. Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells , 1998, International journal of cancer.
[139] A Sette,et al. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). , 1998, Cancer research.
[140] Corman.,et al. Recognition of prostate‐specific antigenic peptide determinants by human CD4 and CD8 T cells , 1998, Clinical and experimental immunology.
[141] Y. Nishimura,et al. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. , 1998, Blood.
[142] A. Sette,et al. Identification of HER2/neu‐derived peptide epitopes recognized by gastric cancer‐specific cytotoxic T lymphocytes , 1998, International journal of cancer.
[143] S. Rosenberg,et al. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. , 1998, Journal of immunology.
[144] C. Farina,et al. Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage , 1998, The Journal of experimental medicine.
[145] Millard,et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells , 1998, British journal of haematology.
[146] Thomas Halder,et al. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells , 1998, Cancer Immunology, Immunotherapy.
[147] K. Schmid,et al. Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study , 1998, Histochemistry and Cell Biology.
[148] F. Lemonnier,et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. , 1998, The Journal of clinical investigation.
[149] P. van Endert,et al. The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytes. , 1998, Cancer research.
[150] J. Patard,et al. An antigen recognized by autologous CTLs on a human bladder carcinoma. , 1998, Journal of immunology.
[151] L. Michaux,et al. LAGE‐1, a new gene with tumor specificity , 1998, International journal of cancer.
[152] F. Lemonnier,et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. , 1998, The Journal of clinical investigation.
[153] Hiroya Kobayashi,et al. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient , 1998, Immunogenetics.
[154] H. Stein,et al. Identification of HLA‐A2‐restricted epitopes of the tumor‐associated antigen MUC2 recognized by human cytotoxic T cells , 1998, International journal of cancer.
[155] J. Shabanowitz,et al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. , 1998, Journal of immunology.
[156] H. Yamana,et al. A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.
[157] T. Boon,et al. Overlapping peptides of melanocyte differentiation antigen melan‐A/MART‐1 recognized by autologous cytolytic T lymphocytes in association with HLA‐B45.1 and HLA‐A2.1 , 1998, International journal of cancer.
[158] D. Jäger,et al. Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.
[159] A. Sette,et al. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. , 1998, Journal of immunology.
[160] S. Kimura,et al. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. , 1998, Cancer research.
[161] A. Monaco,et al. Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. , 1997, Genomics.
[162] A. Sette,et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. , 1997, Cancer research.
[163] A. Sette,et al. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. , 1997, Cancer research.
[164] S. H. van der Burg,et al. Identification of HLA‐A*0201‐restricted CTL epitopes encoded by the tumor‐specific MAGE‐2 gene product , 1997, International journal of cancer.
[165] J. Myklebust,et al. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21‐ras (12VAL) peptide vaccination of a patient, recognize 12VAL‐dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation , 1997, International journal of cancer.
[166] F. Brasseur,et al. A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma , 1997, The Journal of experimental medicine.
[167] J. Guillet,et al. Peptides derived from the whole sequence of BCR‐ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes , 1997, European journal of immunology.
[168] S. Rosenberg,et al. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. , 1997, Journal of immunology.
[169] T. Eberlein,et al. The HER2/neu‐derived peptide p654–662 is a tumor‐associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes , 1997, European journal of immunology.
[170] Yao-Tseng Chen,et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[171] J. Schlom,et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. , 1997, Journal of the National Cancer Institute.
[172] J. Sidney,et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. , 1997, Journal of immunology.
[173] P. Coulie,et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. , 1997, Immunity.
[174] Yutaka Kawakami,et al. Human tumor antigens recognized by T-cells , 1997, Immunologic research.
[175] D. Hunt,et al. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. , 1996, Journal of immunology.
[176] E. Appella,et al. Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes , 1996, The Journal of experimental medicine.
[177] P. van Endert,et al. Characterization of antigenic peptides presented by HLA‐B44 molecules on tumor cells expressing the gene MAGE‐3 , 1996, International journal of cancer.
[178] C. Melief,et al. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. , 1996, Blood.
[179] G. Pawelec,et al. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. , 1996, Blood.
[180] D. Roopenian,et al. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens , 1996, The Journal of experimental medicine.
[181] F. Brasseur,et al. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma , 1996, The Journal of experimental medicine.
[182] A. Sette,et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. , 1996, Blood.
[183] A Sette,et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.
[184] D. Accapezzato,et al. Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes , 1996 .
[185] E. Appella,et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.
[186] G. Parmiani,et al. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[187] S. Rosenberg,et al. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen , 1996, The Journal of experimental medicine.
[188] P. Bruggen,et al. Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.
[189] F. Brasseur,et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene , 1996, The Journal of experimental medicine.
[190] T. Boon,et al. A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes , 1996, European journal of immunology.
[191] D. Accapezzato,et al. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. , 1996, Leukemia.
[192] R. Henderson,et al. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. , 1995, Journal of immunology.
[193] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[194] O. de Backer,et al. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma , 1995, The Journal of experimental medicine.
[195] P. Coulie,et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[196] C. Melief,et al. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. , 1995, Leukemia.
[197] K. Sakaguchi,et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. , 1995, Journal of immunology.
[198] J. Schlom,et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. , 1995, Journal of the National Cancer Institute.
[199] C. Figdor,et al. Identification of a novel peptide derived from the melanocyte‐specific gp100 antigen as the dominant epitope recognized by an HLA‐A2.1‐restricted anti‐melanoma CTL line , 1995, International journal of cancer.
[200] K. Sakaguchi,et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. , 1995, Journal of immunology.
[201] D. Morton,et al. Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. , 1995, Molecular immunology.
[202] J. Wharton,et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.
[203] A. Sette,et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.
[204] R. Brasseur,et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. , 1995, Immunity.
[205] T. Oka,et al. Peptides with carboxyl-terminal sequence of alanine-proline: detection by a human monoclonal antibody. , 1995, Hybridoma.
[206] T. Eberlein,et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[207] M. Lotze,et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.
[208] P. Coulie,et al. A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3 , 1994, European journal of immunology.
[209] S. Rosenberg,et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[210] P. Bruggen,et al. Autologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601 , 1994, European journal of immunology.
[211] K. Sakaguchi,et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[212] K. Sakaguchi,et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[213] J. Renauld,et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.
[214] R. Henderson,et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.
[215] S. Rosenberg,et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[216] B. Seliger,et al. Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes , 1994, European journal of immunology.
[217] P. Romero,et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.
[218] M. Herlyn,et al. Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients , 1993, The Journal of experimental medicine.
[219] P. Pandolfi,et al. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. , 1993, Blood.
[220] Catia,et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.
[221] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[222] W. Ollier,et al. Analysis of HLA antigens on germ cells in human semen , 1989, European journal of immunology.